Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media › C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
10/2003
10/30/2003US20030203469 Efficient purification of adenovirus
10/30/2003US20030203415 Comprises polypeptide for, diagnosis, detection and treatment of cancer
10/30/2003US20030203357 Detecting and differentiating viruses or other intracellular parasites present in a specimen; compositions and methods to evaluate the susceptibility of a organisms to antimicrobial agents
10/30/2003US20030202988 Attenuated mutant; induce immunology response
10/30/2003US20030202987 Hepatitis virus; oligomer protein
10/30/2003US20030202986 Methods and compositions for the selective modification of nucleic
10/30/2003US20030201230 Using a cross-flow filter; chromatography
10/30/2003CA2478009A1 Modified vaccinia virus ankara for the vaccination of neonates
10/30/2003CA2455898A1 Rapid sterilization and vaccine preparation
10/29/2003EP1356071A2 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/29/2003EP0745128B1 Hepatitis b virus mutants, reagents and methods for detection
10/29/2003CN1452496A Use of strains of parapox ovis virus against organ fibrosis
10/29/2003CN1125877C Hepatitis G. Virus and molecular cloning thereof
10/29/2003CN1125876C Broad spectrum efficient septic (CPV) and its bioinsecticide
10/28/2003US6639060 DNA segment encoding a receptor protein related to the erbB proto-oncogene family which previously has not been known; tool for screening for anticancer agents
10/28/2003US6638762 Tissue-vectors specific replication and gene expression
10/28/2003US6638756 Chimeric cell-targeting pathogenic organism and method of therapeutic use
10/28/2003US6638514 Immunogenic attenuated dengue viruses produced by serial passage in primary dog kidney cells
10/23/2003WO2003087371A1 Antiviral therapy on the basis of rna interference
10/23/2003WO2003087365A1 Method of measuring human cyp3a inducibility
10/23/2003WO2003087351A1 Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
10/23/2003WO2003087348A1 Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
10/23/2003WO2003087330A2 Vac-bac shuttle vector system
10/23/2003WO2003087128A2 Secretory signal sequences and uses thereof
10/23/2003WO2003053343A3 Novel compounds that enhance dimerization of the subunits of hiv-1 reverse transcriptase having mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors
10/23/2003WO2003040164A3 Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
10/23/2003WO2003023032A3 High throughput directed evolution by rational mutagenesis
10/23/2003WO2002036806A3 Expression vectors able to elicit improved immune response and methods of using same
10/23/2003WO2002036617A3 A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
10/23/2003WO2001094560A3 In vitro assembly of sv40 viruses and pseudoviruses
10/23/2003US20030199671 For protein isolation and purification
10/23/2003US20030199093 Retroviral packaging system, plasmids and packagable vector transcripts produced from high expression plasmids after stable or transient transfection in mammalian cells
10/23/2003US20030199074 Cold-adapted equine influenza viruses
10/23/2003US20030198947 Hepatitis virus sentinel virus I (SVI)
10/23/2003US20030198650 Equine herpes viruses; hybrid nucleic acid
10/23/2003US20030198649 HBV core antigen particles with multiple immunogenic components attached via peptide ligands
10/23/2003US20030198623 Attenuation Dna; coding cytokines, tumor antigen
10/23/2003CA2849556A1 Preservation of bioactive materials by freeze dried foam
10/23/2003CA2482841A1 Method of measuring human cyp3a inducibility
10/23/2003CA2482395A1 Antiviral therapy on the basis of rna interference
10/22/2003EP1354030A2 Materials and methods relating to increasing viral titre
10/22/2003EP1353956A1 Method for surface display of proteins on genetic carriers
10/22/2003CN1451038A Attenuated influenza virus useful as vaccine
10/22/2003CN1451014A Peptidomimetic protease inhibitors
10/22/2003CN1450910A Mutant simplex virus for treating hyperproliferative cell growth
10/22/2003CN1450173A SARS related coronal virus total genom chip and use thereof
10/22/2003CN1450164A Novel coronal virus strain and medicinal use thereof
10/22/2003CN1450086A Anti SARS specificity IgY and combination preparation thereof
10/22/2003CN1125174C Recombinant phages
10/21/2003US6635752 Diagnosis of Aids
10/21/2003US6635477 Comprising a open reading frame; use in diagnosis, treatment and prevention
10/21/2003US6635466 Adenovirus serotype 30 (Ad30)
10/21/2003US6635257 Oligomeric particle having diameter of 1 to 100 nanometer and consisting of hepatitis C virus envelope proteins, or parts thereof, in which at least one cysteine is alkylated
10/21/2003US6635244 Adenovirus E1B-55K single amino acid mutants and methods of use
10/21/2003CA2066940C Canine coronavirus subunit vaccine
10/16/2003WO2003085138A1 Methods of virus production
10/16/2003WO2003085117A1 Viral vectors comprising a nucleic sequence derived from murine leukemia viruses for gene transfer in cells
10/16/2003WO2003085084A2 Hepatitis c virus sub-genomic replicons
10/16/2003WO2003084479A2 Large scale methods of producing adenovirus and adenovirus seed stocks
10/16/2003WO2003068954A3 Microorganism for genetic therapeutic treatment of proliferative diseases
10/16/2003WO2003068809A3 An herpes simplex virus complex
10/16/2003WO2003064595A3 Recombinant herpesvirus of turkeys and use thereof
10/16/2003WO2003008586A3 Engineering oncolytic viruses
10/16/2003WO2002077211A3 A virus (cryptovirus) within the rubulavirus genus and uses therefor
10/16/2003WO2002029074A3 Genetic immunisation against cervical carcinoma
10/16/2003US20030194801 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
10/16/2003US20030194800 For immunization, generation of packaging cell lines, and production of immunogenic compositions
10/16/2003US20030194743 Binding polypeptides for B lymphocyte stimulator protein (BLyS)
10/16/2003US20030194694 Pure recombinant influenza virus comprising a mutant ion channel protein which lacks or has reduced activity relative to the wild-type
10/16/2003US20030194408 Antibody which specifically binds to at least two variants of an epitope of an HIV-1 Tat protein
10/16/2003CA2478932A1 Large scale methods of producing adenovirus and adenovirus seed stocks
10/16/2003CA2478901A1 Methods of virus production
10/15/2003EP1352960A1 Antiviral therapy on the basis of RNA interference
10/15/2003EP1351978A2 Retrovirus isolated from humans
10/15/2003EP1351974A2 Using viruses to detect or purify proteins
10/15/2003EP1079864B1 Entomopoxvirus vector for delivery and expression of heterologous dna in vertebrate cells
10/15/2003CN1448398A Cotton bollworm molt-regulating transcription factor cDNA and cloning method and recombination application thereof
10/15/2003CN1124159C Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants
10/14/2003US6632670 Recombinant adeno-associated virus (AAV) with reduced levels of helper virus; cells which have been transfected with plasmid comprising nucleotide sequences encoding replication (rep) and capsid (cap) proteins
10/14/2003US6632664 Foreign gene inserted into an untranslated region in the genome
10/14/2003US6632647 Use of strains of parapoxvirus ovis against organ fibrosis
10/14/2003US6632427 Adenoviral-vector-mediated gene transfer into medullary motor neurons
10/14/2003CA2263790C Method for immortalizing cells
10/09/2003WO2003083116A1 Emthod of screening transporter inhibitor
10/09/2003WO2003083094A1 Hbv drug resistance drug resistance detection methods
10/09/2003WO2003083065A2 Improved methods for achieving expression from alphavirus vectors
10/09/2003WO2003082330A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
10/09/2003WO2003034981A3 Prevention of recurrent viral disease
10/09/2003WO2003028432A3 Flexible processing apparatus for isolating and purifying viruses, soluble proteins and peptides from plant sources
10/09/2003WO2003007889A3 Therapeutic agents comprising pro-apoptotic proteins
10/09/2003WO2002102828A3 Chimeric flavivirus vectors
10/09/2003WO2002066629A3 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
10/09/2003WO2002020563A3 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN
10/09/2003US20030190674 Production of anti-self antibodies from antibody segment repertoires and displayed on phage
10/09/2003US20030190332 Engineered viral particle containing a group of co-expressed viral proteins or portions expressed in an edible plant material, adminstering such plant material containing viral vaccine to the gastrointenial mucosa of the patient
10/09/2003US20030190330 Recombinant canine distemper virus vaccine against canine distemper and leishmaniasis
10/09/2003US20030190324 Immunologically significant herpes simplex virus antigens and methods for using same
10/09/2003CA2480382A1 Hbv drug resistance drug resistance detection methods
10/08/2003EP1350840A1 Adaptation sites of PRRSV
10/08/2003EP1349926A2 Complementing cell lines
1 ... 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 ... 267